GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (XSWX:SDZ) » Definitions » Long-Term Debt

Sandoz Group AG (XSWX:SDZ) Long-Term Debt : CHF0 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Long-Term Debt?

Sandoz Group AG's Long-Term Debt for the quarter that ended in Jun. 2024 was CHF0 Mil.

Sandoz Group AG's quarterly Long-Term Debt increased from Jun. 2023 (CHF0 Mil) to Dec. 2023 (CHF3,438 Mil) but then declined from Dec. 2023 (CHF3,438 Mil) to Jun. 2024 (CHF0 Mil).

Sandoz Group AG's annual Long-Term Debt increased from . 20 (CHF0 Mil) to Dec. 2022 (CHF28 Mil) and increased from Dec. 2022 (CHF28 Mil) to Dec. 2023 (CHF3,438 Mil).


Sandoz Group AG Long-Term Debt Historical Data

The historical data trend for Sandoz Group AG's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Long-Term Debt Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Long-Term Debt
27.95 3,437.58

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Long-Term Debt 27.95 - 3,437.58 -

Sandoz Group AG  (XSWX:SDZ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Sandoz Group AG Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines